Helicos BioSciences (FRA:HB4) FCF Margin % : -29.12% (As of Dec. 2011)

View and export this data going back to . Start your Free Trial

What is Helicos BioSciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Helicos BioSciences's Free Cash Flow for the six months ended in Dec. 2011 was €-0.72 Mil. Helicos BioSciences's Revenue for the six months ended in Dec. 2011 was €2.46 Mil. Therefore, Helicos BioSciences's FCF Margin % for the quarter that ended in Dec. 2011 was -29.12%.

As of today, Helicos BioSciences's current FCF Yield % is 0.00%.

The historical rank and industry rank for Helicos BioSciences's FCF Margin % or its related term are showing as below:

FRA:HB4' s FCF Margin % Range Over the Past 10 Years
Min: -29.12 Med: 0 Max: 0
Current: -29.12

FRA:HB4's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.06 vs FRA:HB4: -29.12

Helicos BioSciences FCF Margin % Historical Data

The historical data trend for Helicos BioSciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helicos BioSciences FCF Margin % Chart

Helicos BioSciences Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

FCF Margin %

Get a 7-Day Free Trial

-6,009.00

-5,839.63

-512.52

-272.77

-29.12

Helicos BioSciences Semi-Annual Data
	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11
FCF Margin %	Get a 7-Day Free Trial			-6,009.00	-5,839.63	-512.52	-272.77	-29.12

Competitive Comparison of Helicos BioSciences's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Helicos BioSciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helicos BioSciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Helicos BioSciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Helicos BioSciences's FCF Margin % falls into.

Helicos BioSciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Helicos BioSciences's FCF Margin for the fiscal year that ended in Dec. 2011 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2011 )	/	Revenue (A: Dec. 2011 )
	=	-0.715	/	2.455
	=	-29.12 %

Helicos BioSciences's FCF Margin for the quarter that ended in Dec. 2011 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2011 )	/	Revenue (Q: Dec. 2011 )
	=	-0.715	/	2.455
	=	-29.12 %

Helicos BioSciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Helicos BioSciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Helicos BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Helicos BioSciences Corp (FRA:HB4) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Helicos BioSciences Corp is incorporated in the state of Delaware and was incorporated on May 9, 2003. It is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The Company's products are based on its proprietary True Single Molecule Sequencing (tSMS) technology which enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. The Company's Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies. The Company is subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of its operations and markets.

Helicos BioSciences Headlines

No Headlines